IN8bio's pipeline is exploding with clinical wins! 📈 The stock's shaking off oversold RSI levels and just staged a bullish reversal on Nov 21. That sharp bounce from the $1.56 low on decent volume? That's smart money starting to position for this news flow. The tide is turning. BUY the momentum. #GammaDeltaRising

"IN8bio is dropping science like it's hot! 🔥 With a tidal wave of positive trial data and FDA nods, this biotech’s pipeline is sizzling. The stock just mooned from pennies to $3+—RSI at 98 screams *overbought*, but those WMAs are still playing catch-up. Wild volume spikes say FOMO is real. Chart? Pure chaos (hello, gamma squeeze vibes). Short-term: risky. Long-term: if trials keep delivering, 🚀. Verdict: Hold for now, but keep a *very* close eye—next dip could be golden. #BiotechBets"

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

IN8bio, Inc. INAB: 1.795 USD

Bullish views